Treating heart failure through innovative RNA-therapies
HAYA Therapeutics SA
Incorporated
02.07.2019Headquarters
EpalingesSupport
HAYA Therapeutics is dedicated to treating heart failure through the discovery and development of innovative first-in-class RNA-based therapeutics, with a specific focus on long noncoding RNAs.
News
Two Swiss biotechs clear US regulatory steps for heart and nerve therapies (startupticker.ch)
Swiss biotechs progress across cardiology, oncology and allergy clinical programs (startupticker.ch)
HAYA Therapeutics starts clinical trial for heart disease therapy (venturelab.swiss)
New Startup Innovation Projects set to advance their technologies (startupticker.ch)
2025 WEF Technology Pioneers highlight two Swiss Startups (startupticker.ch)
Un jubilé synonyme de renaissance (startupticker.ch)
HAYA Therapeutics banks $65 million Series A funding (startupticker.ch)
HAYA Therapeutics secures USD 65M to advance RNA-guided therapies for chronic and age-related diseases (venturelab.swiss)
Recognition for Swiss innovators across the globe (startupticker.ch)
Seasoned executives join Swiss startups (startupticker.ch)
Healthtech startups set for growth (startupticker.ch)
Set for growth: startups rely on experienced leaders (startupticker.ch)
The most promising Swiss biotech startups and scale-ups of 2024, according to investors (TOP 100)
HAYA Therapeutics secures USD 1 billion deal with Lilly to target obesity through RNA platform (venturelab.swiss)
HAYA Therapeutics wins Major Collaboration with Lilly (startupticker.ch)
Erfahrene Expertinnen und Experten verstärken Startup-Management (startupticker.ch)
Inaugural European entrepreneur award crowns HAYA Therapeutics Founders (startupticker.ch)
Swiss Economic Awards: 9 Startups im Finale (startupticker.ch)
ZKB Pionierpreis Technopark shortlists 11 startups (startupticker.ch)
Videos and Presentations
Startup Champions Seed Night 2018